Clinical Research Directory
Browse clinical research sites, groups, and studies.
Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score
Sponsor: Washington University School of Medicine
Summary
Multiple neoadjuvant endocrine trials demonstrate that women with good prognosis tumors can be identified. These trials have also demonstrated that there are not adverse effects on overall outcome if women are treated with neoadjuvant endocrine therapy for several months prior to definitive treatment. A new standard of care needs to be defined for elderly women with good prognosis estrogen receptor (ER)+ tumors, since these women may benefit from endocrine therapy alone to treat their cancer without compromising local and distant control. The investigators hypothesize that endocrine therapy alone provides adequate local and systemic control of breast cancer in a subpopulation of women 70 or older with ER+ breast cancer and low Ki67 scores.
Official title: Endocrine Treatment Alone as Primary Treatment for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score
Key Details
Gender
FEMALE
Age Range
70 Years - Any
Study Type
INTERVENTIONAL
Enrollment
50
Start Date
2017-01-17
Completion Date
2032-07-31
Last Updated
2025-07-28
Healthy Volunteers
No
Interventions
FACT-B
The FACT-B (Version 4) is a 37-item measure that contains the four general subscales along with the Breast Cancer-Specific subscale that assesses symptoms/concerns of particular relevance to breast cancer (e.g., body image, arm swelling and tenderness).
Goserelin
Anastrozole
Exemestane
Fulvestrant
Tamoxifen
Archived tissue collection
Locations (1)
Washington University School of Medicine
St Louis, Missouri, United States